浅析FDA对我公司原料药的GMP现场检查

目的：浅析FDA对原料药的GMP现场检查。方法：针对FDA关于原料药GMP现场检查的重点进行详细论述和分析。结果与结论：企业如果建立了扎实的GMP制度，严格执行美国的CGMP，在实事求是的基础上，充分做好现场和文件准备，就可以成功通过FDA的GMP认证现场检查。     

接受FDA检查的几点体会

本文简要叙述了我厂化学原料药接受FDA检查的过程，对FDA检查中特别重视的几个GMP管理问题进行了深入分析，从而为完善原料药GMP管理， 促进我国的原料药打入美国市场提供参考。     

原料药生产企业GMP质量体系缺陷分析与对策研究

目的为完善原料药生产企业GMP质量体系提供参考。方法对85家原料药生产企业GMP认证现场检查中发现的缺陷项目进行统计。结果与结论分析了原料药GMP质量体系中存在的主要问题及其成因,并提出相应的对策。     

从COS搁置谈原料药生产企业如何通过国际认证现场检查

目的:为我国原料药出口生产企业顺利通过国际认证现场检查提供借鉴。方法:跟踪国外原料药进出口相关法规变化,分析我国原料药生产企业欧洲药典适用性证书(COS)被搁置的原因并提出建议。结果与结论:生产现场存在与欧盟《药品生产质量管理规范》(GMP)要求不符的重大缺陷是导致COS被搁置的主要原因,提高原料药生产过程的GMP管理水平是企业顺利通过国际认证现场检查的关键所在。     

浅谈原料药年度质量回顾的编写方法

介绍了产品年度质量回顾在制药企业质量管理和GMP、FDA、COS迎接认证检查中的重要性,详细地介绍了如何编写原料药产品年度质量回顾。     

FDA国外cGMP检查对中国制药企业的影响分析

目的为中国制药企业进入美国市场找出一条合适的途径。方法查阅近年来相关文献,对FDA国外cGMP检查的现状进行分析总结,提出中国企业接受FDA检查的应对措施。结果与结论面对FDA日益严格的GMP监管,中国制药企业只有严格按照FDA cGMP规范指导生产,才能通过FDA现场检查,进入美国市场。     

原料药生产企业如何应对FDA检查

该文介绍了美国食品和药物管理局（FDA）对原料药控制的方式及对企业检查的重点，提出原料药企业应对FDA检查的措施。     

普洛家园又一原料药通过GMP认证现场检查

2009年12月17—18日,浙江普洛家园药业有限公司的原料药匹维溴铵通过了浙江省药品认证中心GMP检查组的GMP认证现场检查。浙江普洛家同药业有限公司是于2008年6月30日取得国内首家匹维溴铵药品注册批件的,是目前国内仅有的3家获批该药原料药的企业之一。匹维溴铵目前依赖进口。浙江普洛家园药业有限公司的匹维溴铵原料药取得GMP证书后即可上市,由此弥补该药国内生产的空白。     

对我国CEP认证现场检查现状的思考

介绍了EDQM的CEP认证现场检查,结合近年来检查结果的数据统计,分析我国企业CEP认证现状.我国原料药生产企业CEP证书被暂停或撤销的主要原因是:企业申报文件与现场不符、不能达到GMP要求以及我国GMP管理与欧盟存在差距等.建议我国企业加深理解CEP认证现行规定、聘请专家培训、关注EDQM现场检查缺陷,做好CEP认证.     

FDA483报告应对策略研究

作为世界上最大的原料药和药品市场,美国2003年的医生处方药品费用为1 792亿美元,这一数目每年都以至少10%的比率增长.美国药品市场对各国制药企业都有着巨大的吸引力,因而FDA每年收到来自境外的药物申请逐年迅速增加,这直接导致FDA对境外制药企业进行cGMP现场检查的工作量急速上升.2004年,FDA对中国制药企业的cGMP现场检查占其境外检查总数的7%,而这一比例随着我国更多的企业进军美国市场将继续上升.目前,如何顺利的通过FDA现场检查是我国很多企业正全力以赴备战的任务.     

WHO原料药预认证程序解析

目的为中国原料药进入国际市场找出一条合适的途径。方法查阅近年来相关文献,对WHO原料药预认证程序进行分析,阐述WHO原料药预认证的重要性。结果与结论深入学习国际组织相关法规,严格按照WHO GMP规范指导生产,接受WHO文档评估和现场检查,是中国原料药参与WHO国际采购、进入国际市场的最佳途径。     

Development Considerations for Nanocrystal Drug Products

Nanocrystal technology has emerged as a valuable tool for facilitating the delivery of poorly water-soluble active pharmaceutical ingredients (APIs) and enhancing API bioavailability. To date, the US Food and Drug Administration (FDA) has received over 80 applications for drug products containing nanocrystals. These products can be delivered by different routes of administration and are used in a variety of therapeutic areas. To aid in identifying key developmental considerations for these products, a retrospective analysis was performed on the submissions received by the FDA to date. Over 60% of the submissions were for the oral route of administration. Based on the Biopharmaceutics Classification System (BCS), most nanocrystal drugs submitted to the FDA are class II compounds that possess low aqueous solubility and high intestinal permeability. Impact of food on drug bioavailability was reduced for most nanocrystal formulations as compared with their micronized counterparts. For all routes of administration, dose proportionality was observed for some, but not all, nanocrystal products. Particular emphasis in the development of nanocrystal products was placed on the in-process tests and controls at critical manufacturing steps (such as milling process), mitigation and control of process-related impurities, and the stability of APIs or polymorphic form (s) during manufacturing and upon storage. This emphasis resulted in identifying challenges to the development of these products including accurate determination of particle size (distribution) of drug substance and/or nanocrystal colloidal dispersion, identification of polymorphic form (s), and establishment of drug substance/product specifications.     

HACCP法确定冻干粉针剂生产系统检查重点的探讨

目的 探索风险管理在药品GMP认证中的应用,用风险管理的原则指导药品GMP认证现场检查.方法 用风险管理工具危害分析和关键控制点（HACCP）的方法,确定冻干粉针剂生产系统现场检查的重点,并列出检查清单.结果与结论 运用风险管理原则,可以合理地分配资源,使药品GMP认证现场检查更具科学性、针对性.     

药品注册生产现场核查助推药品研发全面融入GMP

目的 指明药品研发阶段融入药品GMP管理的必要性及重要性.方法 介绍了药品注册生产现场核查概况,从人员、设施、设备、原辅料和包装材料、样品批量生产过程、质量控制等方面,分析了药品注册生产现场核查的施行对国内生产企业将药品研发纳入GMP体系的促进作用.结果与结论 我国药品生产企业应将药品研发全面融入GMP管理体系之中,而药品注册生产现场核查可以很好地促进药品研发的规范性及GMP的符合性.     

Evaluation of the state of active ingredients in pharmaceutical preparations using fourier transform-Raman difference spectra

To examine the pharmaceutical application of Fourier transform (FT)-Raman spectroscopy, the state of active pharmaceutical ingredients (APIs) in a preparation of several forms was evaluated by investigating the Raman difference spectra between the preparation and excipient. The difference spectra indicated that APIs in alacepril tablets, caffeine sustained-release granules, and quinidine sulfate granules remained unchanged after the manufacturing process. However, the state of sparfloxacin in nanoparticles changed, although it remained unchanged in tablets or powders. These results show that the FT-Raman difference spectrum is expected to be utilized in the field of quality control of crystalline pharmaceutical preparations.     

辽宁省原料药生产企业新版GMP认证检查缺陷分析与对策

目的:为原料药生产企业实施《药品生产质量管理规范(2010年修订)》(简称新版GMP)和提高生产管理水平提供参考。方法:采用回顾性方法,对2011年3月至2013年12月辽宁省12家原料药生产企业在新版GMP认证检查中的缺陷项目进行统计分析。结果与结论:12家企业共发现有161个缺陷项目,其中质量控制与质量保证、文件管理、物料与产品部分存在的缺陷项目最多,分别有36、31、18个,占总缺陷项目数量的比例为22.36%、19.25%、11.18%。主要体现在质量控制实验室管理不规范;文件控制缺乏有效性和缺少重要的控制数据或记录;原辅料管理、不合格中间产品和原料药处理不符合要求等方面。建议各生产企业应深入理解新版GMP内容,全面贯彻质量风险管理和生产全过程管理的理念;加强硬件系统的改造,推进新版GMP的实施;重视软件系统的建设,建立强有力的质量管理体系;提高培训的针对性和有效性,以最大限度地降低药品生产过程中的风险,提高原料药生产管理水平。     

全球制药行业厂房与设施、设备类检查缺陷情况分析

目的：为我国药品监管和行业发展提供参考。方法：对近几年FDA、MHRA、CFDI及辽宁省药品GMP检查中厂房与设施、设备类的缺陷进行统计分析,从缺陷占比、高频缺陷等角度分析GMP检查缺陷在反映制药企业硬件水平方面的重要作用。结果与结论：从GMP检查缺陷角度发现了我国制药行业和发达国家的差距,为我国制药行业在厂房与设施、设备方面改进提出了建议。     

Strategies for preventing occupational exposure to potent compounds

Occupational exposure to active pharmaceutical ingredients in a manufacturing or laboratory environmental can cause unintended health effects in workers handling these compounds. Occupational health professionals in the pharmaceutical industry have responded to this hazard recognition by employing strategies for the risk evaluation and management of potent APIs, otherwise known by the term ‘potent compounds’. The purpose of this paper is to provide an overview of the necessary strategy components for preventing occupational exposure to potent compounds.     

Reimagining drug manufacturing paradigm in today’s pharmacy landscape

The coronavirus disease 2019 pandemic has escalated the ongoing problem of critical medication shortages, which has serious implications for the health of our patients. Currently, active pharmaceutical ingredients (APIs) are synthesized in large-scale batch operations and shipped to drug product manufacturers, where they are produced on a large scale at centralized facilities. In the centralized drug manufacturing process, the formulation components, operations, and packaging are structured to favor long-term storage and shipment of resultant medicines to the point of care, making this process vulnerable to supply chain disruptions. We propose a rethinking of the drug manufacturing paradigm with an upgraded pharmaceutical compounding-based manufacturing paradigm. This paradigm will be based on integration of continuous manufacturing of APIs and manufacturing of medicines at the point of care with application of machine learning, artificial intelligence, and 3-dimensional printing. This paradigm will support implementation of precision medicine and customization according to patients’ needs. The new model of drug manufacturing will be less dependent on the supply chain while ensuring availability of medicines in a cost-effective manner.